Eli Lilly, a private equity firm, completed a $35m investment in Precision BioSciences, a biotechnology company. "Gene-edited therapies are emerging as a promising approach to help patients afflicted with genetic conditions. We look forward to working closely with Precision's scientific team and leveraging their platform to develop and deliver breakthrough medicines for untreated genetic disorders," Ruth Gimeno, Eli Lilly Vice President.